Clinical trials: Diabetic Nephropathy Type 2
Diabetic Nephropathies
Add-on Pentoxifylline to Losartan Versus Increasing Dose of Losartan on NT-PRO BNP in Type 2 Diabetics With Nephropathy
This study was designed to assess the efficacy of adding pentoxifylline to losartan in comparison with increasing dose of losartan in type 2 diabetes patients with nephropathy.
- Trial name
- NCT03006952
- Testing
- Pentoxifylline, Losartan
- Where
- Iran
- Volunteers
- 59 people
- Sponsor
- Tehran University of Medical Sciences
Diabetic Nephropathy
6-Month Safety And Efficacy Study Of TTP488 In Patients With Type 2 Diabetes And Persistent Albuminuria
Current research indicates that TTP488 may be a viable agent for the treatment of diabetic nephropathy. The purpose of this study is to determine the safety and efficacy of a six-month regimen of daily orally-administered TTP488…
- Trial name
- NCT00287183
- Testing
- PF-04494700 (TTP488)
- Where
- 19 sites in Canada
- Volunteers
- 110 people
- Sponsor
- Pfizer
Diabetes Mellitus, Type 2, Cardiovascular Diseases
Clinical Utility of a Genomic Predictor Test on the Management of Cardiorenal Complications of Type 2 Diabetes
The goal of this pragmatic trial is to provide Real World Evidence (RWE) on the impact of the result of a polygenic risk prediction test of cardiorenal complications of T2D, so that more patients at high risk of these…
- Conditions
- Diabetes Mellitus, Type 2, Cardiovascular Diseases, Diabetic Nephropathy Type 2
- Trial name
- GENOCORDIA (NCT06586203)
- Testing
- Polygenic Risk Score
- Where
- 2 sites in Canada
- Volunteers
- 2,714 people
- Sponsor
- Optithera
Diabetes Mellitus, Type 2, Chronic Kidney Disease
Carotid Doppler Screening for Subclinical Atherosclerosis in Diabetic CKD Patients.
This study is being done at Assiut University to look for early signs of hardening of the arteries (atherosclerosis) in people who have both diabetes and chronic kidney disease (CKD).
- Conditions
- Diabetes Mellitus, Type 2, Chronic Kidney Disease, Atherosclerosis
- Trial name
- DiCKD-CAROTID (NCT07266220)
- Volunteers
- 96 people
- Sponsor
- Abdallah Ali Mohammed
Diabetic Nephropathy
Study Of Diabetic Nephropathy With Atrasentan
The study objective was to evaluate the effect of atrasentan compared with placebo on time to doubling of serum creatinine (DBSC) or the onset of end-stage renal disease (ESRD) in participants with type 2 diabetes and nephropathy…
- Trial name
- SONAR (NCT01858532)
- Testing
- Atrasentan
- Volunteers
- 5,107 people
- Sponsor
- AbbVie
Chronic Kidney Disease, Diabetic Nephropathy
A Study of Atrasentan on Reducing Albuminuria in Type 2 Diabetic Nephropathy Treated With Renin-Angiotensin System Inhibitors
The study objective is to investigate the effects of three low doses of atrasentan on urinary albumin/creatinine ratio (UACR) levels in subjects with Type 2 diabetic nephropathy.
- Trial name
- NCT00920764
- Testing
- 0.25 mg Atrasentan QD, 0.75 mg Atrasentan QD, 1.75 mg Atrasentan QD
- Where
- 28 sites in United States, Puerto Rico
- Volunteers
- 92 people
- Sponsor
- AbbVie (prior sponsor, Abbott)
Diabetic Kidney Disease, Obesity
Metabolic Phenotypes of Obesity and Diabetic Kidney Disease in Patients with Type 2 Diabetes Mellitus
1. Comparison between the 4 groups of metabolic phenotypes of obesity as regard the presence and frequency of DKD 2. Relation between DKD , obesity (BMI) and metabolic risk factors in patients with type 2 DM
- Conditions
- Diabetic Kidney Disease, Obesity, Metabolic Syndrome, Diabetes Mellitus, Type 2
- Trial name
- NCT06591104
- Testing
- 24 hour urinary protein
- Volunteers
- 71 people
- Sponsor
- Assiut University
Diabetes Mellitus, Type 2
Post-authorisation Safety Study in Patients With Type 2 Diabetes to Assess the Risk of Liver Injury, Kidney Injury, Urinary Tract and Genital Infections, and Diabetic Ketoacidosis in Patients Treated With Empagliflozin, Compared to DPP-4 Inhibitors
Empagliflozin (Jardiance), a highly potent and selective inhibitor of the sodium-glucose cotransporter 2 (SGLT2), was approved in Europe in May 2014 for the treatment of type 2 diabetes mellitus (T2DM) to improve glycaemic…
- Trial name
- NCT02864914
- Testing
- Empagliflozin, DPP-4 inhibitors
- Where
- United Kingdom
- Volunteers
- 333,580 people
- Sponsor
- Boehringer Ingelheim
Diabetic Nephropathy Type 2
Study of the Protective Effect of Low-dose Aspirin on Renal Function in Patients With Early Diabetic Nephropathy
This is a multicenter, randomized, placebo-controlled study to evaluate the effectiveness and safety of low-dose aspirin (50 mg/day) in renal and cardiac function protection in people with diabetic nephropathy.
- Trial name
- NCT06068439
- Testing
- Acetylsalicylic Acid
- Volunteers
- 355 people
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
Type 2 Diabetes, Overt Diabetic Nephropathy
Effects of Rosiglitazone on Renal Hemodynamics and Proteinuria of Type 2 Diabetic Patients With Renal Insufficiency Due to Overt Diabetic Nephropathy
Objective: To evaluate how rosiglitazone does influence the renal plasma flow, the glomerular filtration rate and the degree of proteinuria in type 2 diabetic patients with renal insufficiency due to overt diabetic nephropathy.
- Trial name
- NCT00324675
- Testing
- Rosiglitazone
- Where
- Germany
- Volunteers
- 28 people
- Sponsor
- Technische Universität Dresden
Chronic Kidney Disease, Diabetic Kidney Disease
A Trial to Learn More About How BAY2327949 Works and How Safe it is in Patients Whose Kidneys Are Damaged Due to High Blood Sugar Levels or High Blood Pressures, and With a Further Disease of the Heart or the Blood Vessels.
In people with type 2 diabetes (T2D), the body makes insulin, but cannot use it well. This results in high blood sugar levels causing damage to the blood vessels inside the kidneys.
- Trial name
- ASSESS-CKD (NCT04661917)
- Testing
- BAY2327949
- Where
- 36 sites in Austria, Denmark and 5 more
- Sponsor
- Bayer
Cardiovascular Disease
Renal Insufficiency And Cardiovascular Events
Reduced glomerular filtration rate (GFR) has been recently shown to be a powerful predictor of cardiovascular morbidity and mortality in the general population, independent of traditional cardiovascular risk factors.
- Trial name
- RIACE (NCT00715481)
- Where
- 20 sites in Italy
- Volunteers
- 15,628 people
- Sponsor
- Diabetic Nephropathy Study Group
Type 2 Diabetes Mellitus, Diabetic Kidney Disease
Finerenone for the Treatment of Type 2 Diabetes-Related Kidney Disease: Efficacy Observation and Related Factor Analysis
This is a single-center prospective observational clinical study conducted at the First Affiliated Hospital of Chongqing Medical University.
- Trial name
- NCT07717697
- Testing
- Finerenone
- Volunteers
- 425 people
- Sponsor
- First Affiliated Hospital of Chongqing Medical University
Diabetic Nephropathy Type 2
the Integrated Traditional Chinese and Western Medicine Treat Middle Stage DKD
Efficacy and Safety of treatment with Traditional Chinese Medicine ShenqiDihuang Decoctions in Patients with middle stage of Diabetic Kidney Disease.
- Trial name
- NCT03681249
- Testing
- ShenqiDihuang Decoction
- Where
- China
- Volunteers
- 112 people
- Sponsor
- Shanghai University of Traditional Chinese Medicine
Diabetic Nephropathy
The Effect of LY333531 on Protein in the Urine in Patients With Type 2 Diabetes
The purpose of this study are to determine 1) Whether Ly333531 can reduce urinary albumin/creatinine excretion in patients with Type II diabetes and persistent albuminuria 2) Whether LY333531 reduces urinary TGF-B, 3) the safety…
- Trial name
- NCT00044148
- Testing
- LY333531
- Where
- 15 sites in United States
- Volunteers
- healthy volunteers welcome
- Sponsor
- Chromaderm, Inc.
Diabetic Kidney Disease, Chronic Kidney Diseases
Prospective Decision Impact Clinical Utility Trial of KidneyIntelX
The clinical utility trial is designed to evaluate how the results of KidneyIntelX test / platform impacts on the clinical management of type 2 diabetes patients identified as increased risk for rapid kidney function decline…
- Conditions
- Diabetic Kidney Disease, Chronic Kidney Diseases, Chronic Kidney Disease Stage 1, Chronic Kidney Disease Stage 2
- Trial name
- NCT05198284
- Testing
- KidneyIntelX
- Where
- United States
- Volunteers
- 2,000 people
- Sponsor
- Renalytix AI, Inc.
Diabetic Kidney Disease
Efficacy and Safety of Finerenone in Subjects With Type 2 Diabetes Mellitus and the Clinical Diagnosis of Diabetic Kidney Disease
The purpose of this study was to evaluate whether oral finerenone (study drug), in addition to standard daily therapy, is effective and safe in treating patients with type 2 diabetes mellitus and diabetic kidney disease, when…
- Trial name
- FIGARO-DKD (NCT02545049)
- Testing
- Finerenone (BAY94-8862)
- Where
- 975 sites in United States, Argentina and 46 more
- Volunteers
- 7,352 people
- Sponsor
- Bayer
Diabetic Nephropathy, Chronic Kidney Disease
Mycophenolate Mofetil, Carnitine and PDE5 Inhibitor, Three Potential Treatments for Resistant Proteinuria Slowing Diabetic Nephropathy Deterioration
Diabetes mellitus (DM) is a growing disease and it is a public health concern, and projections of its future effect are alarming. About one third of those affected will develop diabetic nephropathy at 20 years after diagnosis.
- Trial name
- Myridian (NCT01566006)
- Testing
- Mycophenolate Mofetil (MMF) ,phosphodiesterase 5 inhibitors , CARNITINE
- Where
- Israel
- Volunteers
- 80 people
- Sponsor
- The Nazareth Hospital, Israel
Diabetic Nephropathy, Type 2 Diabetes Mellitus
A Study to Evaluate the Safety and Efficacy of CCX140-B in Subjects With Diabetic Nephropathy
The purpose of this study is to evaluate the safety and efficacy of treatment with CCX140-B in subjects with diabetic nephropathy.
- Trial name
- NCT01447147
- Testing
- CCX140-B
- Where
- 83 sites in Belgium, Czechia and 4 more
- Volunteers
- 332 people
- Sponsor
- Amgen
Diabetic Nephropathy, Dyslipidemia
The Non-high-density Lipoprotein Cholesterol (Non-HDL-C) to High-density Lipoprotein Cholesterol (HDL-C) Ratio (NHHR) and Its Association With Occurrence of Diabetic Nephropathy in Patients With Diabetes Mellitus
The study aims to examine the relationship between the non-high-density lipoprotein cholesterol-to-high-density lipoprotein cholesterol ratio (NHHR) and CKD in patients with DM.
- Trial name
- NCT07476248
- Volunteers
- 84 people
- Sponsor
- Assiut University